Tirzepatide follows a structured dose escalation protocol designed to minimise side effects while gradually increasing the medication's therapeutic effect. Starting at the lowest dose and titrating upward over several months allows the body to adjust to each level before advancing.
Important Medical Notice
Dosing decisions must be made by your prescribing healthcare provider. This guide is for educational purposes only. Never adjust your dose without professional guidance. Your provider will determine the appropriate dose based on your individual response and tolerance.
The Titration Schedule
Tirzepatide uses a step-wise dose escalation starting at 2.5mg. Each dose level is maintained for a minimum of 4 weeks before the healthcare provider considers an increase. The standard titration protocol follows six dose levels:
2.5
mg
Starting Dose
Weeks 1-4 (minimum)
The initial dose is primarily for acclimation. It allows your body to begin adjusting to the medication. Some patients notice mild appetite reduction, but this dose is not intended as the therapeutic target.
5.0
mg
First Therapeutic Dose
Weeks 5-8 (minimum)
The first dose at which meaningful therapeutic effects begin. Many patients report noticeable appetite suppression and early weight changes. This is the minimum maintenance dose for some patients.
7.5
mg
Intermediate Dose
Weeks 9-12 (minimum)
A transitional dose that further increases the dual-agonist effect. Patients typically experience stronger appetite regulation and more consistent weight reduction at this level.
10
mg
Standard Maintenance Dose
Weeks 13-16 (minimum)
Many patients achieve their desired results at this dose. Clinical literature shows substantial weight loss and metabolic improvement at 10mg. Your provider may recommend staying at this level.
12.5
mg
Enhanced Dose
Weeks 17-20 (minimum)
For patients who tolerate lower doses well but require additional weight loss support. Only advanced under medical guidance based on individual response.
15
mg
Maximum Dose
Week 21 onwards
The highest approved dose of tirzepatide. Reserved for patients who have demonstrated good tolerance at lower doses and require maximum therapeutic effect. Clinical studies evaluated outcomes primarily at this dose level.
| Dose | Duration | Purpose |
|---|---|---|
| 2.5 mg | 4 weeks | Acclimation |
| 5.0 mg | 4 weeks | First therapeutic level |
| 7.5 mg | 4 weeks | Intermediate escalation |
| 10 mg | 4+ weeks | Standard maintenance |
| 12.5 mg | 4+ weeks | Enhanced maintenance |
| 15 mg | Ongoing | Maximum dose |
Weekly Injection Timing & Technique
Tirzepatide is administered as a once-weekly subcutaneous injection. Consistency in timing helps maintain stable medication levels and supports treatment adherence.
Timing
- Inject on the same day each week
- Any time of day (with or without food)
- You may change your injection day if needed -- ensure at least 3 days (72 hours) between doses
- Set a weekly reminder to maintain consistency
Injection Sites
- Abdomen (at least 5cm from navel)
- Front of thigh
- Upper arm (back area)
- Rotate sites each week to prevent lipodystrophy
Injection Technique
- Allow medication to reach room temperature (approximately 30 minutes out of refrigerator)
- Clean the injection site with an alcohol swab
- Pinch a fold of skin at the injection site
- Insert the needle at a 90-degree angle (or 45-degree for very thin individuals)
- Inject the full dose slowly and steadily
- Hold the needle in place for 5-10 seconds after injection
- Release the skin fold and withdraw the needle
- Dispose of the used needle in a sharps container
Missed Dose Protocol
If you miss your scheduled injection, the appropriate action depends on how much time has passed:
Within 4 days (96 hours) of scheduled dose
Take the missed dose as soon as possible. Then resume your regular schedule on your next usual injection day.
More than 4 days after scheduled dose
Skip the missed dose entirely. Take your next dose on the regular scheduled day. Do not take two doses at once to make up for a missed dose. Contact your healthcare provider if you have missed multiple consecutive doses.
Never Double Dose
Never inject two doses in one week to compensate for a missed injection. Doubling the dose significantly increases the risk of severe gastrointestinal side effects and potentially dangerous blood sugar fluctuations. If in doubt, contact your healthcare provider.
Storage Requirements
Proper storage is critical for maintaining tirzepatide's potency and safety. The medication is a protein-based peptide that degrades when exposed to heat, and Nigeria's tropical climate makes cold chain management especially important.
Refrigerated Storage
- Store at 2-8°C (36-46°F)
- Keep in the original packaging
- Protect from light
- Do not freeze -- discard if frozen
- Place toward the back of the refrigerator (not in the door)
Room Temperature (if needed)
- May be kept at room temperature (below 30°C / 86°F) for up to 21 days
- Do not return to refrigerator after room temperature storage
- Discard after 21 days at room temperature
- In Nigeria's climate, prioritise refrigeration
Cold Chain in Nigeria
All tirzepatide deliveries in Nigeria should arrive in temperature-controlled packaging with cold packs. Upon receiving your medication:
- Transfer immediately to your refrigerator
- Check the temperature indicator (if provided) to confirm the cold chain was maintained
- If packaging feels warm or the temperature indicator shows a breach, contact your provider before using
- During power outages, keep the refrigerator closed. A full refrigerator maintains temperature for approximately 4 hours without power
Tips for Successful Treatment
- Be patient with titration. The gradual dose increase is designed to minimise side effects. Rushing to higher doses increases the risk of nausea and gastrointestinal discomfort.
- Communicate with your provider. If you experience significant side effects at any dose, your provider may extend the time at that level rather than escalating. There is no requirement to reach the maximum dose.
- Track your progress. Keep a simple weekly log of your weight, appetite changes, and any side effects. This data helps your provider make informed dosing decisions.
- Maintain hydration. Adequate water intake (2-3 litres daily) helps manage the most common gastrointestinal side effects and supports overall metabolic function.
- Prioritise protein intake. As appetite decreases, focus on protein-rich foods to support lean mass preservation. Aim for 1.2-1.6g of protein per kg of body weight daily.
Ready to Begin Treatment?
Get Your Personalised Dosing Plan
Our team will create a dosing protocol tailored to your health profile and goals.
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. Lancet. 2023;402(10402):613-626. PMID: 37385275
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. Lancet. 2021;398(10295):143-155. PMID: 34186022
- Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes. Lancet. 2021;398(10300):583-598. PMID: 34370970
- Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk. N Engl J Med. 2021;385(23):2146-2160. PMID: 34672990
- Eli Lilly and Company. Tirzepatide prescribing information. 2023.
- Dutta D, et al. Efficacy and safety of novel twincretin tirzepatide: A meta-analysis. Indian J Endocrinol Metab. 2021;25(4):251-260. PMID: 35087952
- Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness. Diabetologia. 2022;65(2):225-228. PMID: 34966932
- Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598. PMID: 35210595
Medically Reviewed
This article was reviewed by the Tirzepatide.ng team for accuracy and compliance with current prescribing guidelines. Content is for educational purposes only and does not constitute medical advice. Always follow your healthcare provider's dosing instructions.
Last reviewed: February 2026